CVS Caremark adds Lilly’s Foundayo and Zepbound, erasing Novo’s edge

CVS Caremark will cover Eli Lilly’s oral GLP-1 pill Foundayo from June 1 and restore Zepbound as a preferred option by October 1, completing Lilly’s access across all three major US pharmacy benefit managers.

CVS Caremark will cover Eli Lilly's oral GLP-1 pill Foundayo from June 1 and restore Zepbound as a preferred option by October 1, completing Lilly's access across all three major US pharmacy benefit managers.

POLICY & MARKETS · CARDIO-METABOLIC · JUNE 11, 2026 · UNITED STATES

Formulary leverage in the glucagon-like peptide-1 (GLP-1) obesity market just shifted. CVS Caremark, the largest pharmacy benefit manager (PBM) in the United States, announced on May 28 that it will add Eli Lilly’s oral weight-loss pill Foundayo to its formularies on June 1 and restore Lilly’s injectable treatment Zepbound as a preferred option beginning October 1, according to CVS Caremark’s press release. The decision erases the exclusive formulary advantage that Novo Nordisk had held at CVS since July 2025, when a deal between the two companies made Wegovy the preferred GLP-1 obesity treatment and led CVS to drop Zepbound from covered options.

Lilly confirmed that Foundayo and Zepbound are now covered by all three of the largest PBMs in the US, according to the company’s statement cited by Healthcare Dive. Lilly’s shares rose nearly 6% in early trading on the day of the announcement, per Healthcare Dive reporting.

What the Formulary Shift Means

The commercial significance of the reversal is structural. CVS Caremark’s prior arrangement gave Novo Nordisk a single-supplier preferred position at the country’s largest PBM — a meaningful distribution advantage in a market where formulary tier determines patient out-of-pocket cost and, by extension, prescribing volume. Leerink Partners analyst David Risinger, in a note to clients cited by Healthcare Dive, wrote that the decision ‘reverses that and meaningfully expands the addressable [prescription] pool for Zepbound and Foundayo.’

Novo Nordisk’s senior vice president of market access and public affairs, Tom Scales, stated that both the pill and injectable versions of Wegovy ‘will retain preferred status’ across CVS formularies and that patients currently on Wegovy can remain on the treatment without interruption, according to Fierce Healthcare. The competitive dynamic is now one of parity at CVS rather than exclusion — a materially different position for Lilly than it occupied twelve months ago.

Patient Access and Affordability

Eligible patients with commercial coverage may access Foundayo or Zepbound for as low as $25 per month, according to CVS Caremark’s announcement. A Medicare Part D bridge program is also activating, per the same release. Foundayo is an oral, once-daily GLP-1 with no food or water restrictions, per Lilly’s product description; Zepbound is described in press materials as the most-prescribed injectable weight management medicine in the US.

The practical access expansion is real but not uniform. Individual employers that use CVS Caremark formularies retain the option to exclude the drugs from their specific benefit designs, according to Healthcare Dive. Broad PBM coverage is a necessary condition for patient access — not a sufficient one.

Regulatory and Legal Considerations

The formulary restoration does not resolve all legal exposure from the prior exclusion period. When CVS dropped Zepbound in July 2025 following the Novo Nordisk deal, a class-action lawsuit was filed by Zepbound users who, according to Fierce Healthcare, disputed CVS’s claim that Zepbound and Wegovy were interchangeable. That matter is pending resolution. The new coverage terms are a commercial decision; they do not constitute a legal finding on the interchangeability question at the center of the alleged claims.

Counterpoint

The principal counterargument to reading this as a decisive Lilly victory is the October 1 effective date for Zepbound’s restoration. Foundayo enters preferred coverage on June 1, but the injectable — Lilly’s higher-volume product — does not regain preferred status for another four months. Employers conducting mid-year benefit reviews or annual formulary cycles between June and October will be operating under a formulary in which Zepbound remains excluded. The gap between the two effective dates creates a window in which Novo retains a partial structural advantage for the drug that currently drives the larger share of obesity prescriptions. Whether that window is commercially material depends on employer-level formulary decisions that have not been publicly disclosed.

What to Watch

  1. Employer-level formulary adoption of Foundayo and Zepbound between June 1 and October 1, particularly among large self-insured plan sponsors using CVS Caremark
  2. Resolution or further proceedings in the pending class-action lawsuit filed by Zepbound users following the July 2025 formulary exclusion
  3. Any Novo Nordisk response — pricing, contracting, or access program — designed to defend volume at CVS ahead of Zepbound’s October 1 reinstatement
THE HEALTHSIGNALS BRIEF
A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.
Step 1 of 2 · Free. Work email for instant access. Unsubscribe anytime. By subscribing you agree to receive The HealthSignals Brief by email and accept our Privacy Policy.

The deeper signal is that the GLP-1 formulary war is now being fought on product breadth, not exclusivity. CVS’s statement that ‘ongoing collaboration with pharmaceutical companies is helping to make this in-demand drug class more accessible’ — cited in Fierce Healthcare — reads less as a policy commitment than as a description of the new competitive equilibrium: manufacturers willing to negotiate access terms will be covered alongside rivals, not instead of them. Exclusivity arrangements in this class appear to carry a shelf life.

Lilly’s Path to Full PBM Coverage

1
July 1, 2025
Novo Nordisk preferred deal at CVS takes effect
2
June 1, 2026
Foundayo formulary coverage begins at CVS Caremark
3
October 1, 2026
Zepbound restored as preferred option at CVS Caremark
Key Outcome: All 3 major US PBMs now cover Lilly’s full obesity portfolio. Patient monthly cost from $25 with commercial coverage.
Sources: CVS Caremark press release (May 28, 2026); Fierce Healthcare; Healthcare Dive
THE HEALTHSIGNALS BRIEF

A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.

Built for pharma, market-access, regulatory, policy and investor teams, with the main findings of our gated reports included.

Your subscription could not be validated.
You have successfully subscribed.

Comments

Related